The Millennium Challenge Corporation (MCC) provides a fact sheet (.pdf) detailing its efforts to improve access to water, sanitation and hygiene (WASH) in the developing world. According to the fact sheet, the MCC and its partner countries “have prioritized WASH sector development,” and “MCC has invested $793 million in WASH-related projects in nine partner countries” (3/19).
Private Sector Involvement
VOA News reports on a March 20 panel meeting in Washington, D.C., that highlighted the contributions of corporations and non-governmental organizations (NGOs) to the Global Fund to Fight AIDS, Tuberculosis and Malaria. Chevron, which has “invested $30 million for the three-year period between 2008 and 2011 and has pledged another $25 million through 2013,” was recognized at the meeting as “the first Global Fund Corporate Champion,” according to VOA (DeCapua, 3/23).
The Center for Global Health Policy’s “Science Speaks” blog reports on a panel discussion hosted on Wednesday by the Consensus for Development Reform and the Modernizing Foreign Assistance Network in Washington, D.C. “Foreign assistance experts discuss[ed] the George W. Bush administration’s legacy on global development, focusing on lessons learned and applying them to the next decade and beyond,” and a central theme was the engagement of the private sector, the blog writes. Panelists highlighted the Millennium Challenge Corporation and PEPFAR, according to the blog (Mazzotta, 3/29).
Ethiopia’s new HIV/AIDS workplace policy, instituted in January by the government in cooperation with the country’s main employees’ and employers’ associations, “is expected to protect job seekers from mandatory HIV tests, while facilitating voluntary counseling and testing and defending the right of employees living with HIV to medical leave or job re-allocation,” PlusNews reports. The policy “provides guidelines for the establishment of an AIDS fund to help employees cope with living with the virus” and “stipulates that employers will make the necessary investments to ensure universal precautions in workplaces to protect employees from HIV infection, and … put in place a post-exposure prophylaxis system for their workforce,” the news service writes. Tadele Yimer, president of the Ethiopian Employers Federation, said, “What we hope [the new policy] will do is bring about an agreed consent and uniform approach among employers to fight HIV/AIDS nationally,” according to PlusNews (3/26).
In this interview in World Politics Review’s “Trend Lines,” Peter Navario, an adjunct associate professor of public policy at New York University and a former global health fellow at the Council on Foreign Relations, discusses the evolution South Africa’s HIV/AIDS policy over the last decade, the country’s current relationship with pharmaceutical companies, and how South African President Jacob Zuma’s HIV/AIDS policy is received in the region and by international donors. “South Africa has gone from global laggard to playing a leading role in the global HIV response,” Navario said, adding that the country’s “policies are in lockstep with World Health Organization guidelines, and an aggressive new strategic plan aims to tackle HIV-related stigma, meet 80 percent of treatment need and cut new infections in half by 2016” (3/7).
The “improvement and extension of health care in Africa is … being constrained by gaps in financing,” according to a new report (.pdf) by the Economist Intelligence Unit (EIU) based on research commissioned by Janssen Pharmaceutica, a Belgian subsidiary of Johnson & Johnson, the Financial Times’ “beyondbrics” blog reports (Wheatley, 3/1). The report, titled “The Future of Healthcare in Africa,” “discusses the continent’s traditional health care issues, such as communicable diseases or financing health care in economically difficult circumstances” and “also addresses less well-known topics, such as the threat of obesity and heart disease, the use of mobile technology, development of more preventive care, and more,” according to the Janssen website (3/1). The report “identif[ies] the key trends shaping African health care systems” and uses them “to develop [five] scenarios that depict the possible health landscape on the continent in 2022,” a Janssen press release (.pdf) states (3/1).
“On Monday, the Indian Patent Office effectively ended [German drug maker] Bayer’s monopoly for its [cancer drug] Nexavar and issued its first-ever compulsory license allowing local generic maker Natco Pharma to make and sell the drug cheaply in India,” Reuters reports. “India’s move to strip … Bayer of its exclusive rights to [Nexavar] has set a precedent that could extend to other treatments, including modern HIV/AIDS drugs, in a major blow to global pharmaceutical firms, experts say,” the news service writes, noting, “It is only the second time a nation has issued a compulsory license for a cancer drug after Thailand did so on four drugs between 2006 and 2008.” Thailand also has issued compulsory licenses for HIV/AIDS and heart disease medications, according to Reuters (Kulkarni/Foy, 3/13).
“At a public event [held Tuesday] on Capitol Hill, the Global Fund to Fight AIDS, Tuberculosis and Malaria and Friends of the Global Fight Against AIDS, Tuberculosis and Malaria spotlighted the contributions of public-private partnerships to the Global Fund’s lifesaving work,” a joint press release (.pdf) reports. The event highlighted the “unique and essential roles” that partners like Chevron, the Coca-Cola Company, (RED) and PEPFAR play in improving lives around the globe, “[f]rom assistance in drug delivery, to supplying much-needed resources, to mobilizing consumer markets, to in-country partnerships,” according to the press release. “The partners highlighted at the Capitol Hill event have not only provided funding, but have also brought their individual expertise to the Global Fund, sharing their knowledge and building bridges between the public, private and health sectors,” the press release states (3/20).
The Bill & Melinda Gates Foundation is “to give $220 million over five years to the non-profit biotech firm Aeras to develop vaccines to fight tuberculosis [TB], a company statement said Thursday,” Agence France-Presse reports (3/15). The “grant will allow Aeras to advance several vaccine candidates into pivotal large-scale efficacy trials in South Africa and elsewhere,” South Africa’s Health-e writes (Thom, 3/15). According to AFP, Aeras “has developed six possible TB vaccines that are being tested across Africa, Asia, Europe and America” (3/15).
PAHO Press Release Responds To Reuters Article, Says Private Sector Not Involved In Decision-Making Processes
“The Pan American Health Organization (PAHO) strongly disagrees with the allegations in the recent Reuters article that the food and beverage industry advises our policymaking” with respect to non-communicable diseases (NCDs), the agency said in a press release on Saturday. “In line with PAHO Member States mandates and the Declaration of the United Nations High-Level Meeting on Non-Communicable Diseases held in New York in September 2011, PAHO adheres to a comprehensive approach to fight NCDs, which includes governments, civil society, academia, international organizations, and private sector,” the press release states, adding, “The goal is to work together to raise awareness, promote new and innovative initiatives, and share best practices on the prevention and control of NCDs, as well as in health promotion and behavioral changes.” The press release describes how PAHO works to “manage potential conflicts of interest and ensure transparency and independence in the Organization’s decision-making process,” and the release states, “Private companies are not involved in health policies formulation or in decision-making processes of the Organization” (10/20).